This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Bifunctional purine biosynthesis protein PURH.
Human | |
---|---|
Gene Name: | ATIC |
Uniprot: | P31939 |
Entrez: | 471 |
Belongs to: |
---|
PurH family |
5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMPcyclohydrolase; 5-aminoimidazole-4-carboxamide-1-beta-D-ribonucleotidetransformylase/inosinicase; AICAR formyltransferase/IMP cyclohydrolase bifunctional enzyme; AICAR; AICARFT; AICARFT/IMPCHASE; bifunctional purine biosynthesis protein PURH; IMPCHASE; phosphoribosylaminoimidazolecarboxamide formyltransferase/IMP cyclohydrolase; PURHFLJ93545
Mass (kDA):
64.616 kDA
Human | |
---|---|
Location: | 2q35 |
Sequence: | 2; NC_000002.12 (215311974..215359745) |
ATIC markers have many applications. This article will highlight some of them. These uses include Stem cell research, Gene therapy, and High-affinity primary antibodies. If you're not familiar with ATIC markers, you can read more about them in the links below. For more information, please visit Boster Bio. This website is updated regularly with the latest information about ATIC markers. It's easy to get started.
Boster Bio is a leading supplier of rabbit monoclonal antibodies. Their proprietary PCD platform provides the highest affinity clones for Diagnostics & Therapeutics applications. The PCD process utilizes flow cytometry and proprietary chemistry to prevent B cells from secreting antibodies while maintaining them on the cell membranes. The clones are then incubated with flurochrome-conjugated antigens or proteins and plasma cells. The brightest clones are then isolated for downstream screening.
Picokine(tm) is a highly sensitive ELISA platform that improves sensitivity to the picogram level. The Picokine (tm) ELISA kit was validated with a wide range of samples. Image-based immunohistochemistry can save researchers 30 minutes with Picoband(tm). Its proprietary optimization system produces antibodies with high affinity and minimal cross-reactivity, enabling accurate detection of many different peptides and proteins in biological assays.
When comparing four anti-ricin primary antibodies from Boster Bio, we found that the most common metric for affinity was the dissociation constant. Four of the antibodies measured in the KD range were close to the detection limit and had high affinity to their epitope. The other two did not fit into this pattern. Their KD values, however, were below the detection limit. Hence, we recommend that these antibodies are rated according to their affinity to ricin.
In addition to its proprietary technology and excellent quality control, Boster's antibody products are highly regulated. For the highest quality control, the antibodies are manufactured in Boster's own facilities. These laboratories are ISO-9001 certified. Moreover, the company provides customization and BeNeLux deliveries. A wide variety of antibodies are available in the Boster catalog. They can be ordered in quantities from just a single batch to thousands.
ELIS ELISA assays use similar principles to other immunoassay technologies, relying on specific antibodies to bind antigens, and on a detection system to show whether they have bound to the target antigen. High-affinity primary antibodies are essential for this type of assay, and Boster Bio has developed the techniques for achieving this. Scientists around the world rely on Boster Bio high-affinity antibodies to improve their experiments.
Primary antibodies are immunoglobulins produced in the host body, and are only effective when they bind to specific antigens. Primary antibodies can be classified into two different types: monoclonal and polyclonal. The first type, polyclonal, is made by immunizing a host animal with specific antigens. The latter is a highly specific type and is useful for measuring the antigen of interest.
Monoclonal antibodies were developed in the 1950s by Georges Kohler and Cesar Milstein. The next step in antibody development was the phage-display method, which began the era of rational design. In the 1980s, the development of monoclonal antibodies moved from hijacking the adaptive immune system to rational design. Boster Bio developed monoclonal antibodies to address a variety of diseases.
Single cell counts were performed on samples containing at least 500 cells and percentages were calculated as positives or negatives per sample. In order to identify the most viable stem cell population, the acinar tissue was isolated from a small pancreatic duct. The acinar duct has been associated with other cell populations that express primitive or undifferentiated markers, including pancreatic small cells and nestin proteins.
Adult stem cells have more potential to develop into specific tissue types, but they are likely to contain a higher number of abnormalities due to environmental hazards and errors in replication. In addition to being more flexible, adult stem cells are more adaptable to various conditions. Researchers are using these cells in research trials to determine whether they are appropriate for clinical use. These cells can also be programmed into specialized stem cell populations, such as the heart, liver, or lung, to test the effects of drugs.
Studies of endometrial cyclical renewal began in 2004. Two studies confirmed that stromal and epithelial stem cells were present in the endometrium. The researchers were able to identify the stem cells by a method known as label-retaining cells. They found that these cells display high proliferative potential. Moreover, the ATIC marker was also found in human embryonic stem cells, which are often misidentified in other laboratory settings.
The concept of plasticity in adult stem cells opens the door to the possibility of developing therapies that can repair failing organs. Stem cell therapies have also been used in the transplantation of organs to people with specific illnesses. In addition to transplanting healthy heart muscle, the treatment of certain degenerative diseases may eventually involve the use of adult stem cells. In the meantime, the potential for developing new therapies is endless. So, if the ATIC gene is discovered, researchers can begin developing stem cell treatments and therapies that may improve the quality of life of patients with the disease.
Human stem cells have been described for the first time in 2006. They have multipotent and immunomodulatory properties and have the ability to differentiate into several lineages in vitro. They have also contributed to tissue regeneration and repair in different in-vivo models. The research on the human liver stem cells has yielded over 15 peer-reviewed articles and a Phase 1 study. There is much more to learn about the stem cells in human liver.
Adult stem cells are responsible for growth, homeostasis, and repair in various tissues. Their ability to balance self-renewal with differentiation and lineage determination is crucial for the normal functioning of tissues. Several factors regulate stem cell activity and function in normal adult tissues. The specialized cells secrete signals and cell surface molecules to control their proliferation and determine the fate of their progeny. The stem cell niche hypothesis was proposed in 1978 by David Schofield. The niche hypothesis suggests that adult stem cells reside in fixed compartments within tissues.
A recent FDA approval of a cancer-targeting gene therapy vector called Rexin-G has boosted the hopes of patients with a wide variety of solid tumors. The drug, which carries a cytocidal cyclin G1 construct, possesses several advantages over its predecessors. First, the compound contains a 3:1 mixture of non-transformed chondrocytes and transduced allogenic cells. This combination increases the expression of transforming growth factor-b1.
This drug is a form of gene therapy that carries a high price tag. It is currently the most expensive gene therapy in the market. It is an alternative for patients with severe combined immunodeficiency, a condition that is often the result of immune system failure and can result in life-threatening opportunistic infections. However, the drug's price tag isn't the only problem. There are many other treatments for ADA-SCID patients, and they include immunosuppressive drugs, including transfusions of stem cells.
The development of new gene therapies is a significant advancement in the field of genetics and recombinant DNA technology. Thousands of human clinical trials are underway. As the field continues to advance, hope for patients suffering from life-threatening diseases grows. The increased prevalence of genetic diseases and clear guidelines for gene manipulation are key factors in the advancement of the field. One important step forward is the approval of gene therapy for rare and life-threatening diseases.
In addition to testing the potential for targeted gene therapies, CRISPR has provided a new tool for cancer research. This new technique has revolutionized the way scientists study cells and their functions. The results from CRISPR-Cas9 screens indicate that several enhancer elements are required for p53-induced senescence in lung cancer cells and ERa-positive breast cancer cells to grow. Moreover, these enhancer elements are known to be active only in specific cancer types, and they could become therapeutic targets. These genes also often contain protein-coding genes that are expressed in non-malignant cells.
PMID: 8567683 by Rayl E.A., et al. The human purH gene product, 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase. Cloning, sequencing, expression, purification, kinetic analysis, and domain mapping.
PMID: 8867801 by Yamauchi M., et al. Isolation of human purH gene expressed in the rodent transformant cells by subtractive enrichment of 3'-untranslated region of human transcript.